Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

Emerson Electric Co (EMR) reports robust order growth and increased earnings, despite facing headwinds in Europe and China.

Engineering and automation solutions company Emerson (NYSE:EMR) met Wall Streets revenue expectations in Q4 CY2025, with ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript February 5, 2026 Adaptive Biotechnologies ...

Emerson’s fourth quarter results received a positive market response, as the company met Wall Street’s revenue expectations ...

Emerson Electric (NYSE:EMR) reported first-quarter fiscal 2026 results that management said reflected “disciplined execution” ...

Most readers would already be aware that Emerson Electric's (NYSE:EMR) stock increased significantly by 8.8% over ...

Understand the advantages of PC-driven hearing tests over legacy equipment in terms of cost, scalability, and usability.

Investors will scrutinize the path to profitability. The company expects to achieve positive adjusted EBITDA and positive ...

Moving to an automatic referral for moderate or severe AS may be an option in some situations, with opt-out caveats.

Q1 2026 earnings call: order growth, raised EPS guidance, margin outlook, AI automation and risks in Europe/China.

Explore how electronic medical records revolutionize healthcare by enhancing patient safety, accessibility, and quality of ...